BioAge Labs, Inc (BIOA NASDAQ) stock market data APIs
$19.8381
0.52(2.6%)
as of February 12, 2026
Try our APIs with
free plan!
BioAge Labs, Inc Financial Data Overview
Price chart is built with
Anychart
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Prev. Close
19.8381
Open
20.3604
High
20.877
Low
19.4996
52 wk Range
2.88-24
Market Cap
833 M
P/E Ratio
1.4651
Shares Outstanding
41 752 K
Revenue
5 917 K
EPS
-0.56
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with BioAge Labs, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioAge Labs, Inc data using free add-ons & libraries
Get BioAge Labs, Inc Fundamental Data
BioAge Labs, Inc Fundamental data includes:
- Net Revenue: 5 917 K
- EBITDA: -89 528 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.5137
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioAge Labs, Inc News
New
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early...
Assessing BioArctic (OM:BIOA B) Valuation After Recent Share Price Momentum
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why BioArctic is on investors’ radar today BioArctic (OM:BIOA B) has recently dra...
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation t...
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candid...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
